drugset / Trial / NCT02275065
Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegravir (GS-9883) in Human Immunodeficiency Virus (HIV)-1 Infected Participants
RandomizedSequentialQuadruple-blindTreatment
Summary
The primary objective of the study is to investigate the short-term antiviral potency of bictegravir at multiple doses in antiretroviral (ART) treatment-naive adult participants and participants who are ART-experienced but integrase strand transfer inhibitor (INSTI) naive.
Timeline
- Start
- 2014-10-24
- Primary completion
- 2015-01-23
- Completion
- 2015-01-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | bictegravir | Small molecule | 5 mg | Oral |
| Subject | bictegravir | Small molecule | 25 mg | Oral |
| Subject | bictegravir | Small molecule | 50 mg | Oral |
| Subject | bictegravir | Small molecule | 100 mg | Oral |